Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
source: pixabay.com

Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma

  A recent announcement by Gilead Company citing data from Kite Pharma, one of its premier companies, set out remarkable results from Kite’s Zuma-1 clinical trial. The findings confirmed that…

Continue Reading Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
source: pixabay.com

Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay

As reported in PR NewsWire;  in an effort to help the entirety of the sickle cell disease community, Emmaus Life Sciences, Inc has announced a program that will provide their…

Continue Reading Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
Elite Gamer Holiday Charity Tournament Raises $42K for Cure Rare Disease
https://pixabay.com/photos/xbox-game-console-games-console-4117267/

Elite Gamer Holiday Charity Tournament Raises $42K for Cure Rare Disease

Looking for a feel-good story? Then look no further. In December, telecom company Cox worked to make a difference for the rare disease community. The organization headed its Elite Gamer…

Continue Reading Elite Gamer Holiday Charity Tournament Raises $42K for Cure Rare Disease
Report from the Neurological Alliance Calls for Improvements for Rare Neurological Disease Patients
kreatikar / Pixabay

Report from the Neurological Alliance Calls for Improvements for Rare Neurological Disease Patients

The Neurological Alliance has released a report that details the experiences that rare, neurological disease patients in the UK share and calls for improvements for these people. Experts in the…

Continue Reading Report from the Neurological Alliance Calls for Improvements for Rare Neurological Disease Patients

A CRISPR Tool With the Potential to Halt the Progression of Sickle Cell and Beta Thalassemia

According to an NBC AP news item, early results show that CRISPR, a “tool” that alters DNA permanently in blood cells, has the potential to not only stop the progression…

Continue Reading A CRISPR Tool With the Potential to Halt the Progression of Sickle Cell and Beta Thalassemia
The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases
source: pixabay.com

The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases

  A recent article in the Encinitas Advocate heralded the dedication of Stan Crooke, n-Lorem Foundation’s CEO and founder. The nonprofit Foundation’s team acts as middlemen, working with patients who…

Continue Reading The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases
Artificial Intelligence Could Improve Drug Development, But it Faces Obstacles
https://pixabay.com/en/technology-robot-human-hand-2025795/

Artificial Intelligence Could Improve Drug Development, But it Faces Obstacles

Many medical professionals have applauded artificial intelligence and machine learning in the drug development process for a long time, as they can increase the speed while decreasing the cost. However,…

Continue Reading Artificial Intelligence Could Improve Drug Development, But it Faces Obstacles